The molecule contains one methionine residue (Met-27) susceptible to oxidation, requiring inert atmosphere handling for long-term storage [1][5]
A newer iteration of TTOAD2, termed TTP273, is in clinical trials, and early, unpublished results suggest it is highly effective for blood glucose control ( Another oral small molecule GLP1 receptor agonist (PF06882961) has also been recently described which shares a similar mode of GLP1 receptor binding with LY3502970 but, interestingly, shows only a minor degree of bias in favour of cAMP over arrestin recruitment (Griffith et al., 2020
Oral semaglutide should be taken on an empty stomach, which may influence the choice of formulation
In this scenario, compounding pharmacies, which are overseen at the state and federal level, would obtain active ingredients from FDA-registered manufacturers